Application of IDO1 inhibitor in preparation of medicine for treating sepsis-related thymic atrophy of children

By inhibiting IDO1 activity, reducing the accumulation of Kyn and blocking the activation of AhR, the problem of impaired immune function in sepsis patients is solved, thymus atrophy and immune function are improved, and the prognosis of sepsis patients is improved.

CN119700754APending Publication Date: 2025-03-28CHILDRENS HOSPITAL OF FUDAN UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202411921908.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-25
Publication Date
2025-03-28

AI Technical Summary

Technical Problem

Immune function in patients with sepsis is impaired, especially T lymphocyte depletion, which leads to thymus atrophy and impaired immune response. The existing treatment methods are limited.

Method used

By inhibiting the activity of IDO1, reducing the accumulation of Kyn, blocking the activation of AhR, thereby reducing ferrodystrophy of thymocytes and improving thymus atrophy and immune function.

Benefits of technology

Inhibition of IDO1 activity can improve sepsis-related thymus atrophy, restore T cell output and survival, and improve immune function and prognosis in sepsis patients.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicine, and discloses application of IDO1 as a target spot in preparation of a medicine for treating sepsis-related thymic atrophy in children and application of a substance for inhibiting the activity of IDO1 in preparation of a medicine for treating sepsis-related thymic atrophy in children, and the substance for inhibiting the activity of IDO1 comprises 1-methyltryptophan as an IDO1 inhibitor, 1-methyltryptophan as an IDO1 inhibitor, 1-methyltryptophan as an IDO1 inhibitor and 1-methyltryptophan as an IDO1 inhibitor. The IDO1 inhibitor 1-methyltryptophan improves the accumulation of Kyn and improves the thymic atrophy, the number of thymic output T cells and the survival of the thymic output T cells. The application disclosed by the invention reveals that ferroptosis participates in the sepsis-related thymic atrophy process for the first time, molecular biology experiments show that IDO1 activates thymic cell ferroptosis signals through a Kyn-AhR pathway, sepsis-related thymic atrophy can be improved by targeting IDO1-Kyn-AhR pathway, a potential immunotherapy scheme is provided for clinical treatment of sepsis, and the application has a wide application prospect. The immunologic function and the overall prognosis of sepsis patients are expected to be improved.
Need to check novelty before this filing date? Find Prior Art